UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2005
GTx, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
005-79588
(Commission
File Number)
|
|
62-1715807
(I.R.S. Employer
Identification No.) |
3 N. Dunlap Street
3rd Floor, Van Vleet Building
Memphis, Tennessee 38163
(901) 523-9700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
(Former name or former address, if changed since last report)
TABLE OF CONTENTS
ITEM 8.01 Other Events.
On September 7, 2005, GTx, Inc. announced results
of its Phase I clinical trials and its Phase II development plans for ostarine, GTx’s second selective androgen receptor modulator
compound to be tested in clinical trials.
The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
ITEM 9.01 Financial Statements and Exhibits.
(c) Exhibits
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
99.1
|
|
Press Release issued by GTx, Inc. dated September 7, 2005 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
|
|
|
|
| |
GTx, Inc.
|
|
| Date: September 7, 2005 |
By: |
/s/ Henry P. Doggrell
|
|
| |
|
Name: |
Henry P. Doggrell |
|
| |
|
Title: |
Vice President, General Counsel/Secretary |
|
| |